Considerations and recommendations for assessment of plasma protein binding and drug–drug interactions for siRNA therapeutics

At the time of writing, although siRNA therapeutics are approved for human use, no official regulatory guidance specific to this modality is available. In the absence of guidance, preclinical development for siRNA followed a hybrid of the small molecule and biologics guidance documents. However, siR...

Descripción completa

Detalles Bibliográficos
Autores principales: Humphreys, Sara C, Davis, John A, Iqbal, Sajida, Kamel, Amin, Kulmatycki, Kenneth, Lao, Yanbin, Liu, Xiumin, Rodgers, John, Snoeys, Jan, Vigil, Adam, Weng, Yan, Wiethoff, Christopher M, Wittwer, Matthias B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Critical Reviews and Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226521/
https://www.ncbi.nlm.nih.gov/pubmed/35687098
http://dx.doi.org/10.1093/nar/gkac456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226521/
https://www.ncbi.nlm.nih.gov/pubmed/35687098
http://dx.doi.org/10.1093/nar/gkac456

Ejemplares similares